Yazar "Channa, Roomasa" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim Yok
    Öğe
    Comparison of Visual Field Parameters in Early and Advanced Stages of Multiple Sclerosis Patients Without a History of Optic Neuritis
    (Taylor & Francis As, 2013) Guler, Mete; Turkcuoglu, Peykan; Yilmaz, Turgut; Yoldas, Tahir Kurtulus; Channa, Roomasa
    This study compared the visual field parameters of multiple sclerosis patients without optic neuritis in early versus advanced stage of the disease. Patients were divided into two groups: group 1 (early stage, n = 14) constituted of patients with Expanded Disability Status Scale scores <3 and group 2 (advanced stage, n = 13) constituted of patients with Expanded Disability Status Scale scores >= 3. Mean visual acuities in both groups were similar (p = 0.674). Mean sensitivity, mean defect, loss of variance, reliability factor parameters (Octopus 101 perimeter) of groups 1 and 2 were 24.17 +/- 3.62, 21.81 +/- 3.04; 4.14 +/- 3.05, 6.49 +/- 2.58; 21.61 +/- 22.17, 33.31 +/- 18.67; and 1.57 +/- 2.79, 2.59 +/- 3.09, respectively. Compared with group 1, mean sensitivity was significantly lower in group 2 (p = 0.013). Mean defect (p = 0.004) and loss of variance (p = 0.042) parameters in group 2 were significantly higher than in group 1. Mean reliability factor was similar between two groups (p = 0.211). Multiple scleorisis may alter visual field parameters without severe loss of visual acuity by possibly involving optic pathways other than optic nerve.
  • Küçük Resim Yok
    Öğe
    Intercellular Adhesion Molecule Inhibitors as Potential Therapy for Refractory Uveitic Macular Edema
    (Taylor & Francis Inc, 2010) Wang, Jianmin; Ibrahim, Mohamed; Turkcuoglu, Peykan; Hatef, Elham; Khwaja, Afsheen; Channa, Roomasa; Do, Diana V.
    Purpose: To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema. Methods: A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections. Results: After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation. Conclusion: Further investigation of the role of intercellular adhesion molecule inhibitors in the management of uveitic macular edema is indicated.
  • Küçük Resim Yok
    Öğe
    Mycophenolate Mofetil and Fundus Autofluorescence in the Management of Recurrent Punctate Inner Choroidopathy
    (Informa Healthcare, 2011) Turkcuoglu, Peykan; Chang, Peter Y.; Rentiya, Zubir S.; Channa, Roomasa; Ibrahim, Mohamed; Hatef, Elham; Sophie, Raafay
    Methods: Eight patients who had at least two recurrent episodes of increased activity before MMF and 12 months of documented clinical course before and after MMF were included. The frequencies of attacks before and after MMF were compared. FAF images evaluated. Results: Before MMF, the 8 patients experienced 19 attacks of recurrent disease activity; during MMF therapy, 3 (38%) patients experienced 6 recurrent episodes. The attack frequencies were 1.09 +/-+/- 0.75 before and 0.23 +/-+/- 0.32 during treatment (p == .036). Among the 6 patients who had FAF, surrounding hyperautofluorescent halo was detected in 4 and recurrence occurred in 2 who did not show any changes on the intensity during treatment. Conclusion: In the index study, the employment of MMF has decreased frequency of attacks in recurrent PIC. FAF may be employed to monitor and predict the response to treatment.